Cannabis Goes to Schedule III: What Hemp Operators Need to Understand About the New Federal Two-Tier System

Big news came out of Washington in April 2026 — but the full story is more nuanced than the headlines suggest. The DOJ and DEA finalized a narrower Schedule III rule covering FDA-approved marijuana products and state-regulated medical marijuana, effective April 28, 2026. The broader proposed rescheduling of marijuana in general? Still in formal rulemaking, with hearings kicking off June 29, 2026. What's taking shape is an emerging two-tier federal framework, and hemp operators need to understand it — even though neither development changes hemp's status under the 2018 Farm Bill. For the specific final rule, see DEA Final Rule — FDA-Approved Marijuana Products (Apr. 28, 2026); for the broader rescheduling process, see DEA Proposed Rulemaking — Rescheduling of Marijuana (Apr. 28, 2026). Federal cannabis and hemp policy is a moving target — always verify current status at federalregister.gov before making compliance decisions.

Three things matter most for hemp operators right now: taxation, regulatory registration, and banking access. These apply directly to operators covered by the April 2026 final rule, and they'll carry more weight if the broader proposed rescheduling moves forward. The 2018 Farm Bill still governs hemp, defining it as cannabis with no more than 0.3% delta-9 THC on a dry weight basis Farm Bill 2018. Under that framework, compliant hemp isn't treated as a Schedule I or II controlled substance — though that's a general reading of current federal law, not legal advice tailored to your specific situation. For operators and products within the scope of the April 2026 final rule, the Schedule III shift creates a separate regime with real tax and banking consequences. The internal tax code at stake is 26 U.S.C. §280E, which has historically blocked Schedule I and II businesses from taking ordinary deductions — in the new framework, that changes for qualifying medical cannabis operators in ways that simply don't apply to hemp Internal Revenue Code §280E.

Tax landscape and 280E relief. Medical cannabis operators stand to gain meaningful relief from 280E-type restrictions under the Schedule III regime, unlocking ordinary business deductions that were previously off the table. Hemp operators, though, keep working under hemp-specific tax treatments tied to the Farm Bill — a different playbook entirely. Talk to your tax professional and stay current on IRS guidance, because how 280E actually shakes out in a Schedule III context depends heavily on how agencies like the IRS and DOJ choose to implement and interpret the rules. For background, see Internal Revenue Code §280E.

Regulatory pathways and DEA registration. The April 2026 final rule opens up new DEA registration pathways for entities working with FDA-approved marijuana products and covered state-regulated medical marijuana — a formalized channel that simply didn't exist before. Hemp, on the other hand, keeps its registration posture under the Farm Bill; there's no Schedule III classification for hemp. For operators outside the final rule's scope, what comes next on broader regulatory pathways depends on whether the proposed rulemaking for general marijuana rescheduling actually advances. Keep tabs on the latest at DEA Scheduling.

Banking access and financial services. The banking picture for cannabis operators is shifting, driven by the federal-to-state divergence and the Schedule III step. Financial institutions have long navigated complicated and evolving guidance around cannabis, and this shift may gradually reduce the perceived risk for medical cannabis operators — improving their access to banking services. That said, hemp operators shouldn't assume they'll see identical treatment. For a regulatory-financial lens, see FinCEN Guidance on Marijuana-Related Businesses.

State-specific context for target states. California and Michigan have mature cannabis markets with established licensing regimes — they'll still need to work through how to fold the Schedule III changes into their tax and banking practices. Indiana and Kentucky take a more conservative approach, prioritizing hemp and medical cannabis governance within their own frameworks. Colorado's well-developed cannabis program is a useful case study for watching how a state market responds when federal policy starts moving on scheduling. One thing holds true across all five states: hemp and cannabis rules aren't uniform and change constantly. Operators in every state should verify current requirements with their state hemp or cannabis agency before making compliance decisions. Across all five markets, hemp operators should stay focused on Farm Bill compliance and state control measures — and keep a close eye on federal signals around tax and banking.

Quotes from Tom Lavigne. "This shift to Schedule III for medical cannabis creates a visible bifurcation in the federal landscape—a path that benefits medical operators on tax and regulatory access, while hemp remains anchored to the 2018 Farm Bill," explains Tom Lavigne, attorney. "Hemp operators should now plan for a landscape where the two regimes demand different operational playbooks, especially around deductions, registrations, and banking." Tune in to the iHemp Content podcast for the full discussion with Tom Lavigne, and catch the MI Tech News video on YouTube for the interview at the channel MI Tech News: https://www.youtube.com/@Mitechnews/. The quote above reflects those themes discussed in the episode.

Conclusion and call to action. The Schedule III development doesn't change hemp's legal status — but it does reshape the competitive landscape for operators who cross paths with medical cannabis markets. Hemp operators should stay sharp on Farm Bill compliance, keep up with regulatory interpretations as they develop, and stay engaged with hemp advocacy communities to make sure policy remains balanced and practical across state programs. Learn more at iHemp International and stay connected with updates that matter to the broader hemp ecosystem.